Remove 2029 Remove Biosimilars Remove Drug Pricing
article thumbnail

Market outlook to 2032: future trends across the seven major markets

European Pharmaceutical Review

“The dominance of the US within the 7MM is due to its larger insomnia population and higher drug prices. GlobalData considered drug pricing and market exclusivity to be two major obstacles. GlobalData considered drug pricing and market exclusivity to be two major obstacles.

article thumbnail

CMS Finalizes Guidance on Medicare Part D Manufacturer Discount Program

FDA Law Blog: Biosimilars

The manufacturer’s agreement must cover all its labeler codes that contain an applicable drug or a selected drug. The primary manufacturer of a selected drug may also request CMS to terminate its agreement if they are unwilling to participate in the Medicare Drug Price Negotiation.

Labelling 105